Bayer Looks To Singapore To Develop Cancer Drugs For Asian Patients
This article was originally published in PharmAsia News
NEW DELHI - Bayer Schering Pharma Asia Pacific, a unit of Germany-based Bayer Schering Pharma AG, and the Yong Loo Lin School of Medicine of the National University of Singapore will team up to develop novel cancer-fighting drugs targeted specifically at Asian patients
You may also be interested in...
BEIJING - After receiving regulatory approval to sell the liver cancer drug Nexavar in China, executives at Bayer HealthCare Pharmaceuticals indicated the country could become the biggest market in the world for the compound
Pfizer Head of R&D Business Development-Asia Alex Fowkes On Developing R&D Strategies For Asia: An Interview With PharmAsia News (Part 1 of 2)
Pfizer Head of R&D Business Development-Asia Alex Fowkes sat down recently with PharmAsia News' Australia bureau to discuss Pfizer's research and business development strategies in Asia. Fowkes recently addressed a panel at the BioAsia conference in Singapore and discussed Pfizer's virtual networking approach to doing business in Asia, which offers more flexibility and creative approaches (PharmAsia News, May 8, 2008).
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).